Immuneering (NASDAQ:IMRX) CEO Purchases 2,400 Shares

Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin Zeskind acquired 2,400 shares of the stock in a transaction on Tuesday, June 23rd. The shares were acquired at an average price of $4.56 per share, with a total value of $10,944.00. Following the purchase, the chief executive officer owned 2,315,252 shares in the company, valued at $10,557,549.12. This represents a 0.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Immuneering Price Performance

Shares of NASDAQ:IMRX traded up $0.06 during midday trading on Wednesday, reaching $4.60. The company had a trading volume of 1,294,550 shares, compared to its average volume of 1,511,254. The stock has a market capitalization of $297.61 million, a P/E ratio of -3.93 and a beta of 0.38. Immuneering Corporation has a one year low of $2.87 and a one year high of $10.08. The stock’s fifty day moving average price is $5.01 and its 200-day moving average price is $5.27.

Immuneering (NASDAQ:IMRX) last issued its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.09. As a group, sell-side analysts forecast that Immuneering Corporation will post -1.12 earnings per share for the current year.

Institutional Trading of Immuneering

Several large investors have recently added to or reduced their stakes in IMRX. Empery Asset Management LP bought a new stake in Immuneering in the fourth quarter worth $17,601,000. State Street Corp lifted its position in shares of Immuneering by 1,289.7% during the 4th quarter. State Street Corp now owns 2,402,238 shares of the company’s stock worth $15,807,000 after purchasing an additional 2,229,374 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Immuneering by 128.5% in the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after acquiring an additional 1,358,322 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Immuneering in the third quarter worth $6,602,000. Finally, Blue Owl Capital Holdings LP acquired a new position in Immuneering during the 3rd quarter valued at $3,850,000. 67.65% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Chardan Capital reissued a “buy” rating and issued a $20.00 price target on shares of Immuneering in a report on Tuesday, May 19th. Wall Street Zen cut shares of Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Immuneering in a report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research report on Friday, March 27th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.50.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.